ÂÜÀòÂÒÂ×

Enping Hong, PhD, has over 15 years of experience in the field of biomedical research and development. Enping is currently serving as Principal Scientist in Preclinical Research at Senti Biosciences, where they lead a team in delivering IND-enabling studies for the company's pipeline programs. Enping mentors and manages a team of four research staff members, ensuring cohesion, efficiency, and effective resource distribution.

Prior to joining Senti Biosciences, Dr. Hong worked as a Senior Scientist in Preclinical Research at the same company, focusing on supporting IND-enabling studies for pipeline programs. Enping played a key role in designing and executing safety and efficacy studies for the development of SENTI-202, a lead CAR-NK cell therapy for AML. In addition, they authored and contributed to nonclinical study reports for regulatory filings.

Before their time at Senti Biosciences, Dr. Hong held positions at Ascendis Pharma as Associate Principal Scientist and Senior Scientist in Oncology. In these roles, they designed and executed preclinical studies to support the company's Oncology portfolio and served as a subject matter expert in flow cytometry. Enping specifically designed, tested, and implemented multicolor flow cytometry panels for in vitro and in vivo studies.

Dr. Hong also gained experience at Rubius Therapeutics as a Scientist in Immuno-oncology, where they evaluated therapeutic candidates for immuno-oncology applications. Enping'sresponsibilities included assessing potential Red Cell Therapeutic candidates for immunotherapeutic efficacy.

During their tenure at the National Cancer Institute (NCI), Dr. Hong worked as a Postdoctoral Fellow in the Immunology group of the Nanotechnology Characterization Lab. Enping conducted research studying the immune response of primary human PBMCs to novel nucleic acid-based nanoparticles, resulting in multiple published manuscripts. Enping also co-developed a nanoformulation for cancer vaccine applications by evaluating its efficacy for antigen delivery.

Dr. Hong began their career as a Doctoral Student and Postdoctoral Associate in the Fahmy Lab of Biomedical Engineering at Yale University. Enping'sresearch involved developing biodegradable polymeric nanoparticles for cancer immunotherapy and designing a nanoparticle-mediated delivery system for IL-15 to enhance T cell activation by dendritic cells.

Enping also gained experience as a PhD Rotation Student in the Kyriakides Lab of Pathology and Pharmacology at Yale School of Medicine, where they conducted histological tissue analysis and co-authored a manuscript on the foreign body response.

Dr. Hong's previous experience includes working as an Undergraduate Research Fellow in the Reichert Lab of Biomedical Engineering at Duke University, where they compared endothelial progenitor cells between healthy volunteers and patients with coronary artery disease. Enping also served as an Infantry Officer in the Singapore Armed Forces, overseeing physical fitness tests for reserve soldiers.

Overall, Dr. Enping Hong has a strong background in biomedical research, with expertise in preclinical studies, flow cytometry, nanoparticle development, and immunotherapy. Enping has made significant contributions to the development of innovative therapeutics throughout their career.

Enping Hong, PhD has a diverse educational background in the field of biomedical engineering. Enping earned their Doctor of Philosophy (Ph.D.) degree in Biomedical Engineering from Yale University, where they studied from 2009 to 2014. Prior to that, they completed their Bachelor of Science in Engineering degree in Biomedical Engineering at Duke University from 2006 to 2009. Enping Hong completed their high school education at Raffles Institution from 1998 to 2003, obtaining a High School Degree. In addition to their formal education, Enping Hong has also obtained a certification as a Project Management Professional from the Project Management Institute in May 2017.